Pityriasis rubra pilaris is a rare inflammatory skin disease marked by rough, follicular bumps and salmon-to-orange-red plaques that can spread to cover most of the body, often leaving behind distinctive patches of completely normal-looking skin called “islands of sparing.” It affects both children and adults, is frequently confused with psoriasis, and can range from a limited nuisance to a debilitating condition that disrupts sleep, movement, and temperature regulation. The science behind PRP has advanced considerably in the past decade, with genetic discoveries pointing toward specific immune pathways and newer biologic drugs offering relief where older treatments fall short.
What PRP Looks Like on the Skin
The hallmark features of PRP tend to follow a recognizable pattern, though the disease can look different from person to person. It typically begins with small, rough, reddish bumps centered on hair follicles. These bumps gradually merge into broader plaques that take on the characteristic salmon or orange-red color. In a large case series of 100 patients, the most common findings included follicular plugging, the salmon-colored plaques with islands of sparing, prominent redness over the elbows and knees, thickened skin on the palms and soles, and fine scaling on the scalp.1JAMA Dermatology. Epidemiologic, Clinicopathologic, Diagnostic, and Management Challenges of Pityriasis Rubra Pilaris: A Case Series of 100 Patients In many cases the disease progresses to erythroderma, meaning the redness and scaling eventually cover the vast majority of the body’s surface.2PubMed. Erythrodermic pityriasis rubra pilaris treatment: Two case reports and literature review
The islands of sparing are one of the most useful clues for recognizing PRP. These are well-defined patches of completely uninvolved skin surrounded by areas of redness and scaling. They can appear anywhere on the body and often catch the eye immediately against the background of inflamed skin. The palms and soles also deserve attention: the thick, waxy, yellowish buildup there is so common that it functions almost like a calling card for the disease, particularly in children.
Why PRP Is So Often Misdiagnosed
Getting the right diagnosis is one of the biggest hurdles people with PRP face. Research suggests that only about half of patients with classic PRP were correctly diagnosed at their initial visit. The most common misdiagnoses include psoriasis, contact dermatitis, and eczema, and roughly 2% of patients were initially told they had a fungal infection. Perhaps most telling, about 54% of patients needed two or more skin biopsies before the diagnosis was finally established.3American Journal of Case Reports. Early Presentation of Pityriasis Rubra Pilaris Mimicking Tinea Corporis: Diagnostic Challenges of a Rare Skin Condition
The confusion with psoriasis is understandable. Both diseases produce red, scaly plaques and can cover large areas of the body. Under the microscope, though, PRP tends to show a distinctive “checkerboard” pattern in the outer layer of skin, with alternating columns of different types of thickening.4PubMed. Pityriasis Rubra Pilaris: An Updated Review of Clinical Presentation, Etiopathogenesis, and Treatment Options Additional microscopic clues include follicular plugging, a thickened granular layer, and a type of cell separation not typically seen in psoriasis.5PubMed. The clinical and histomorphological features of pityriasis rubra pilaris. A comparative analysis with psoriasis Even with these differences, the overlap is significant enough that experienced dermatopathologists sometimes need to correlate biopsy findings with what they see clinically before they are confident in the diagnosis.
The Six Subtypes
PRP is not a single disease so much as a family of related conditions. The most widely used framework divides it into six subtypes based on the patient’s age when symptoms start, how far the disease spreads, its expected course, and whether the patient has HIV.6PubMed. A Review on Pityriasis Rubra Pilaris The classic adult-onset form, called Type I, accounts for roughly 55% of all cases.7PubMed Central. Successful treatment of type I pityriasis rubra pilaris with ixekizumab It tends to start on the head and work its way down, eventually producing widespread redness with the telltale islands of sparing. Type II, the atypical adult form, is rarer and more chronic.
Types III and IV mirror the adult subtypes but start in childhood. Type III is the classic juvenile form, while Type IV is the circumscribed juvenile form, which stays limited to the elbows, knees, and sometimes the palms and soles. In one series of 28 children with confirmed PRP in Taiwan, Type IV was far more common than Type III, appearing in about 86% of juvenile cases. Two thirds of those children had a prolonged course lasting more than three years, which is longer than some earlier studies had suggested.8PubMed. Juvenile pityriasis rubra pilaris: report of 28 cases in Taiwan
Type V is an atypical juvenile form with early onset, often present from birth or the first years of life. Type VI is defined by its association with HIV infection, and any new diagnosis of PRP should prompt screening for HIV.9PubMed. A Review on Pityriasis Rubra Pilaris
What Causes PRP
For most people who develop PRP, a clear-cut cause is never found. The disease appears to arise from a collision of genetic susceptibility and some kind of external trigger, though the relative weight of each factor varies by subtype.
The most significant genetic breakthrough came with the identification of mutations in a gene called CARD14. Researchers found that families with inherited PRP carried mutations in this gene, which is expressed specifically in the skin and activates an inflammatory signaling pathway called NF-κB. The same gene, interestingly, is also mutated in some families with psoriasis, which helps explain the clinical overlap between the two diseases.10PubMed Central. Familial pityriasis rubra pilaris is caused by mutations in CARD14 Subsequent work confirmed that Type V PRP in particular, both familial and sporadic cases, is driven by CARD14 mutations, including de novo mutations that appear for the first time in a child rather than being inherited.11JAMA Dermatology. Pityriasis Rubra Pilaris Type V as an Autoinflammatory Disease by CARD14 Mutations
As for what sets off the disease in people without a strong family history, a scoping review of the literature found that the most commonly reported triggers included COVID-19 vaccination, underlying malignancy producing a paraneoplastic eruption, and COVID-19 infection itself.12PubMed Central. Updates on Pityriasis Rubra Pilaris: A Scoping Review Other infections have also been linked: two pediatric cases were triggered by respiratory syncytial virus (RSV) during episodes of bronchial illness.13PubMed. Post-infectious pityriasis rubra pilaris in pediatric patients The common thread seems to be immune activation, whether from infection, vaccination, or a cancer sending aberrant signals to the skin. None of these triggers guarantee PRP; they appear to unmask the disease in someone whose immune system is already primed for it.
The Immune Pathways Involved
Understanding the specific immune circuits that drive PRP has been one of the more productive areas of recent research, largely because it points directly toward treatments. Analysis of inflamed PRP skin has revealed elevated levels of several key inflammatory signals. These include TNF, IL-6, IL-12, IL-23, and IL-1β from the innate immune system, along with a strong upregulation of Th17 cytokines like IL-17A, IL-17F, and IL-22.14PubMed. Interleukin 23-Helper T Cell 17 Axis as a Treatment Target for Pityriasis Rubra Pilaris This IL-23/IL-17 axis is the same pathway targeted by many of the newer biologic drugs used in psoriasis, which is partly why dermatologists began repurposing those drugs for PRP.
A 2024 nonrandomized trial further confirmed this picture using protein and gene expression profiling. Patients who later responded well to treatment showed dysregulation of Th17 and NF-κB pathways, tying the molecular findings back to the CARD14 gene mutations identified years earlier.15JAMA Dermatology. Guselkumab for Pityriasis Rubra Pilaris and Dysregulation of IL-23/IL-17 and NFkB Signaling: A Nonrandomized Trial The picture that emerges is of a disease where a genetic tendency toward overactive NF-κB signaling in the skin, once provoked by an immune trigger, drives an exaggerated Th17 inflammatory response that feeds on itself.
HIV-Associated PRP
Type VI PRP deserves separate attention because it behaves differently from all the other subtypes. It occurs in people living with HIV and is thought to result from an abnormal immune response to antigens, compounded by direct HIV infection of hair follicle cells. Vitamin A deficiency and problems with retinol-binding protein, which are more common in advanced HIV, may also play a role. Clinically, Type VI stands apart through the presence of nodulocystic folliculitis, an inflammatory condition affecting hair follicles that is not seen in the other subtypes.16PubMed Central. HIV-Associated Pityriasis Rubra Pilaris Type 6: First Case Report from Türkiye
The treatment implications are straightforward: antiretroviral therapy is the primary intervention for Type VI, and it can lead to complete clearance. In one reported case, a patient with significant immune suppression was started on antiretroviral therapy along with acitretin, a systemic retinoid, and responded well within two months.17PubMed Central. Pityriasis rubra pilaris type 6: A case report in an AIDS patient In another case, antiretroviral therapy alone achieved complete regression within three months.18PubMed Central. HIV-Associated Pityriasis Rubra Pilaris Type 6: First Case Report from Türkiye Because PRP can be an early sign of undiagnosed HIV, screening is advised for all newly diagnosed cases.
The Physical Toll Beyond the Skin
PRP is sometimes described as “just a skin condition,” but the symptoms extend well beyond appearance. A mixed-methods study that surveyed people living with PRP found that the physical burden includes severe itch, widespread pain in affected skin, painful fissures on the palms and soles, joint pain, poor sleep, chronic fatigue, inability to sweat normally, problems regulating body temperature, buildup of material in the ears, and a runny nose.19JEADV Clinical Practice. The comprehensive impact of pityriasis rubra pilaris on physical symptoms, mental health, and activities of daily living: A mixed methods study The inability to sweat and resulting difficulty with temperature control can make exercise, outdoor work, and even warm weather genuinely dangerous.
Many of these symptoms are invisible to others, which compounds the psychological burden. When a person’s skin is covered in painful, flaking plaques and their hands crack and bleed from normal daily tasks, the impact on work, relationships, and self-image can be profound. Sleep disruption from itch and pain creates a cycle of fatigue that affects every part of life. These realities matter for treatment decisions, because even a partial reduction in disease severity can translate into meaningful improvements in function and well-being.
Treatment Options
There is no treatment specifically approved for PRP by most regulatory agencies, so management relies on drugs borrowed from other inflammatory skin diseases. Retinoids, particularly acitretin, have traditionally been considered the first-line systemic treatment.20PubMed Central. Management of refractory pityriasis rubra pilaris: challenges and solutions Retinoids work by slowing the overproduction of skin cells and reducing inflammation, and they help some patients considerably. However, refractory cases that either fail to respond or relapse after the drug is stopped are well recognized, and side effects like dry skin, lip cracking, and potential effects on blood lipids limit long-term use.
When retinoids fall short, biologic drugs targeting specific immune molecules have increasingly filled the gap. TNF-alpha blockers like infliximab and etanercept were among the first biologics tried. In a small case series of adults with refractory Type I PRP, both drugs produced complete and lasting responses. Infliximab worked faster, while the overall treatment duration was similar for both.21PubMed. Treatment of refractory adult-onset pityriasis rubra pilaris with TNF-alpha antagonists: a case series
More recently, drugs that target the IL-17 and IL-23 pathways have shown strong promise. A literature review found that agents like secukinumab and ixekizumab (IL-17 inhibitors) and ustekinumab (which blocks both IL-12 and IL-23) produced meaningful improvements in disease severity scores, and early clinical trials suggest secukinumab and ixekizumab may be particularly effective at achieving remission.22PubMed. Biologics for Treatment of Pityriasis Rubra Pilaris: A Literature Review In one case report, a patient treated with ixekizumab saw noticeable improvement within two weeks and complete clearance of redness and scaling within six weeks of the first injection.23Case Reports in Dermatology. Successful Treatment of Pityriasis Rubra Pilaris with Ixekizumab
A single-arm clinical trial of ixekizumab in 12 patients provided more systematic data. Three quarters of participants achieved a meaningful improvement in quality-of-life scores by week 24, with average itch and pain ratings each dropping by about 3.6 points on a 10-point scale.24JAMA Dermatology. Evaluation of Ixekizumab Treatment for Patients With Pityriasis Rubra Pilaris: A Single-Arm Trial Guselkumab, an IL-23 inhibitor, has also been studied in a nonrandomized trial, with proteomic profiling helping to identify which patients are likely to respond.25JAMA Dermatology. Guselkumab for Pityriasis Rubra Pilaris and Dysregulation of IL-23/IL-17 and NFkB Signaling: A Nonrandomized Trial The field is moving toward using molecular profiling to match patients with the biologic most likely to work for them, though this approach is still in its early stages.
Supportive and Topical Care
Whatever systemic treatment a patient receives, day-to-day skin care makes a real difference. When PRP progresses to erythroderma, the massive loss of skin barrier function can lead to fluid loss, temperature instability, and secondary infections, sometimes severe enough to require hospitalization for fluids and wound care. Emollients are the backbone of topical management: heavy moisturizers applied frequently help reduce cracking and discomfort. Calcipotriol, a vitamin D analogue applied topically, is sometimes used alongside emollients to help normalize skin-cell turnover in affected areas.
Practical adjustments also matter. Because many patients with widespread PRP cannot sweat normally, staying cool in warm environments becomes a deliberate effort rather than something the body handles on its own. Fissures on the hands and feet can make gripping objects and walking painful, so protective gloves, padded insoles, and barrier creams for the palms and soles are common parts of a daily routine. These measures do not treat the disease itself, but they address the symptoms that affect daily life most directly while systemic treatments take time to work.
Prognosis and Natural Course
The outlook depends heavily on subtype. For the most common form, classic adult Type I, about 80% of cases resolve on their own within three years, even without treatment.26PubMed Central. Successful treatment of type I pityriasis rubra pilaris with ixekizumab That statistic, while encouraging, comes with an important caveat: three years of severe skin disease is a long time to wait for spontaneous clearance, and “resolution” may not mean the disease never returns. Treatment is therefore pursued not just to speed clearance but to reduce suffering during what can be a prolonged active phase.
The juvenile subtypes can follow a different trajectory. While some cases of classic juvenile PRP (Type III) also clear within a few years, the circumscribed juvenile form (Type IV) proved more stubborn in at least one large series, with two thirds of children experiencing disease lasting more than three years.27PubMed. Juvenile pityriasis rubra pilaris: report of 28 cases in Taiwan Type V, the atypical early-onset form linked to CARD14 mutations, tends to be chronic and lifelong. Type II (atypical adult) also follows a more persistent course. The takeaway is that while PRP as a whole has a better natural history than many chronic skin diseases, the variation between subtypes is wide enough that generalizing from the 80% resolution figure can be misleading for patients whose subtype follows a different pattern.
PRP in Children
Childhood PRP has some features that distinguish it from the adult forms beyond just the age of onset. Thickened palms and soles appear to be an especially prominent feature in children, functioning almost as a cardinal sign in pediatric cases.28PubMed. Juvenile pityriasis rubra pilaris: report of 28 cases in Taiwan The distribution of subtypes also differs: while Type I dominates in adults, Type IV was by far the most common in the Taiwanese pediatric series, outnumbering Type III roughly six to one.
Treatment in children adds another layer of complexity. Acitretin, the standard first-line retinoid in adults, did not show clear dose- or time-dependent improvement in the six children who received it in that same study. This does not necessarily mean retinoids never work in pediatric PRP, but it reinforces that children are not simply small adults when it comes to this disease. Biologic therapies are increasingly used off-label in pediatric dermatology, but data specific to children with PRP remain scarce, and treatment decisions often rely on expert judgment and extrapolation from adult evidence. For families navigating this, connecting with a dermatologist experienced in PRP is more valuable than any single drug recommendation, because the treatment path often involves trial and adjustment over months.
When PRP Accompanies Cancer
One of the more unsettling associations in the PRP literature is the link with underlying malignancy. A scoping review identified malignancy as the second most commonly reported trigger, with cases described as paraneoplastic PRP eruptions.29PubMed Central. Updates on Pityriasis Rubra Pilaris: A Scoping Review Paraneoplastic skin eruptions are not caused by the cancer invading the skin directly but rather by the immune system’s response to the tumor producing skin changes at a distance. In these cases, treating the underlying cancer can sometimes lead to improvement or resolution of the PRP.
This association is worth knowing about, though it should be kept in proportion. The vast majority of PRP cases are not paraneoplastic. Still, when PRP appears for the first time in an older adult, particularly if it does not fit neatly into the usual Type I pattern or does not respond to standard treatment, clinicians may consider age-appropriate cancer screening. The association is one more reason why PRP warrants thorough evaluation rather than a quick prescription and follow-up.